REG - daVictus Plc - Publication of a Prospectus

daVictusAnnouncement

21/02/2020 14:20

RNS Number : 7854D
daVictus plc
21 February 2020
 


21 February 2020
 
daVictus plc
("daVictus" or "Company")
 
PROSPECTUS PUBLICATION AND ADMISSION TO LISTING ON THE OFFICIAL LIST AND TO TRADING ON THE LONDON STOCK EXCHANGE
 
The board of daVictus Plc (LON: DVT) is pleased to announce that a prospectus relating to: (i) the Company's conditional acquisition by way of a reverse takeover of the intellectual property rights in a restaurant concept owned by Typical Dutch N.V. ("TDNV");  (ii) the placing of 900,000 new ordinary shares of no par value at 15 pence per share; and (iii) the admission of 12,150,00 ordinary shares of no par value to the Official List (by way of Standard Listing under Chapter 14 of the Listing Rules) and to trading on the London Stock Exchange's Main Market for listed securities ("Admission") was approved by the Financial Conduct Authority on 19 February 2020.
 
The prospectus has been published in electronic form and will shortly be available on the Company's website http://www.davictus.co.uk/page/uploads/readmission-prospectus.pdf and from the Company's registered office at JTC PLC, 28 Esplanade, St Helier JE1 8SB, Jersey.
 
In accordance with the Listing Rules, the listing of the enlarged issued share capital, under the name of daVictus Plc, is expected to occur at 8.00 a.m. on 25 February 2020.
 
A further announcement will be made at Admission.
 
Dealing Code
 
ISIN : JE00BYY5RQ34
SEDOL : BYY5RQ3
TIDM : DVT
 
End
 
For further information, please contact:
 
Sara Chawankon (Ms)
Investor Relations Team
ir@davictus.co.uk
 
Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/7854D_1-2020-2-21.pdf




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDIEALAFAEKEEFA